1) The document discusses continuous manufacturing technologies for solid dose drug formulations, including continuous powder-to-tablet manufacturing lines and direct compression processes. 2) Continuous manufacturing can provide benefits over batch processes like reduced manufacturing times, waste, and costs through improved efficiency and flexibility. 3) Excipient properties must support the needs of continuous manufacturing, such as ensuring stable flow and mixability. Multifunctional excipients and premixes may help address this. 4) The document explores how specific Merck KGaA excipients like Parteck M, Parteck ODT, Parteck Delta M, and Parteck SRP 80 can enable different continuous manufacturing application areas like wet